Phyllanthus
Antiproliferative activity of the main constituents from Phyllanthus emblica. (1/31)
Eighteen main compounds, including four norsesquiterpenoids (1-4) and 14 phenolic compounds (5-18) isolated previously from Phyllanthus emblica, together with a main constituent, proanthocyanidin polymers (19) identified at this time from the roots, were estimated for their antiproliferative activities against MK-1 (human gastric adenocarcinoma), HeLa (human uterine carcinoma), and B16F10 (murine melanoma) cells using an MTT method. All of the phenolic compounds including the major components 5-8 from the fruit juice, 8, 9, and 12 from the branches and leaves, and 19 from the roots showed stronger inhibition against B16F10 cell growth than against HeLa and MK-1 cell growth. Norsesquiterpenoid glycosides 3 and 4 from the roots exhibited significant antiproliferative activities, although their aglycon 1 and monoglucoside 2 showed no inhibitory activity against these tumor cells. (+info)Inhibition of aldose reductase by tannoid principles of Emblica officinalis: implications for the prevention of sugar cataract. (2/31)
PURPOSE: Aldose reductase (AR) has been a drug target because of its involvement in the development of secondary complications of diabetes including cataract. Although numerous synthetic AR inhibitors (ARI) have been tested and shown to inhibit the enzyme, clinically synthetic ARIs have not been very successful. Therefore, evaluating natural sources for ARI potential may lead to the development of safer and more effective agents against diabetic complications. In the present study we have assessed the inhibition of AR by constituents of Emblica officinalis both in vitro and in lens organ culture. METHODS: E. officinalis is widely used against many chronic ailments including diabetes. Aqeous extract of E. officinalis and its major constituent tannoids were tested for inhibition against both rat lens and purified recombinant human AR. ARI potential of isolated tannoids of E. officinalis were also investigated against osmotic stress in rat lens organ culture. RESULTS: E. officinalis extract inhibited rat lens and recombinant human AR with IC50 values 0.72 and 0.88 mg/ml respectively. Since E. officinalis is a rich source of ascorbic acid, we investigated whether ascorbic acid was responsible for AR inhibition by E. officinalis extract. However, ascorbic acid did not inhibit AR even at 5 mM concentration. Further, we demonstrate that the hydrolysable tannoids of E. officinalis were responsible for AR inhibition, as enriched tannoids of E. officinalis exhibited remarkable inhibition against both rat lens and human AR with IC50 of 6 and 10 microg/ml respectively. The inhibition of AR by E. officinalis tannoids is 100 times higher than its aqueous extract and comparable to or better than quercetin. Furthermore, the isolated tannoids not only prevented the AR activation in rat lens organ culture but also sugar-induced osmotic changes. CONCLUSIONS: These results indicate that tannoids of E. officinalis are potent inhibitors of AR and suggest that exploring the therapeutic value of natural ingredients that people can incorporate into everyday life may be an effective approach in the management of diabetic complications. (+info)Modulation of haematopoetic system and antioxidant enzymes by Emblica officinalis gaertn and its protective role against gamma-radiation induced damages in mice. (3/31)
The radio protective effect of the fruit pulp of Emblica officinalis Gaertn (Emblica) was studied in adult Swiss albino mice. Mice were treated with 2.5 g/kg b.wt of Emblica for 10 consecutive days before irradiation and exposed to a single dose of 700 rads (7Gy) of radiation after the last dose. One group was given Emblica continuously for another 15 days after irradiation. Changes in the total leukocyte count, bone marrow viability and hemoglobin were studied after whole body irradiation. Administration of Emblica significantly increased these levels, which were lowered by irradiation. Animals were sacrificed at various time points after irradiation and the activities of the antioxidant enzymes catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GPX), and glutathione-S-transferase (GST), and levels of glutathione were assayed in the blood. The damage to the cell membrane after whole body irradiation was studied by measuring the tissue lipid peroxides levels. Administration of Emblica significantly enhanced the activity of the various antioxidant enzymes and GST as well as glutathione system in the blood. Treatment with Emblica also lowered the elevated levels of lipid peroxides in the serum. The data clearly indicated that the extract significantly reduced the bioeffects of radiation. Emblica extract may be useful in reducing the side effects produced during therapeutic radiation. (+info)Reversal of fibrogenic events in liver by Emblica officinalis (fruit), an Indian natural drug. (4/31)
A hydroalcoholic (50%) extract of Emblica officinalis (fruit) (EO-50) reduced the severity of hepatic fibrosis induced by carbon tetrachloride (CCl4) and thioacetamide (TAA). Improved liver function was observed by measuring the levels of aspartate aminotransaminase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) and bilirubin in serum. Hepatic parameters monitored were the levels of glutathione (GSH), lipid peroxidation (LPO) and hydroxyproline and the activities of catalase, glutathione peroxidase (GPx), Na+,K+-ATPase and cytochrome P450 (CYP 450 2E1) (aniline hydroxylation). The results suggested that EO-50 effectively reversed profibrogenic events possibly due to its promising antioxidative activity. (+info)Antiatherogenic effects of phyllanthus emblica associated with corilagin and its analogue. (5/31)
Oxidized low-density lipoprotein (ox-LDL) is the main etiologic factor in atherogenesis, and antioxidants are accepted as effective treatment of atherosclerosis. The aim of this study was to clarify whether the mechanism of the antiatherogenic effects of the herb Phyllanthus Emblica, which is widely used to treat atherosclerosis-related diseases, is associated with ox-LDL via its compounds of soluble tannin, corilagin (beta-1-O-galloyl-3,6-(R)-hexahydroxydiphenoyl-d-glucose), and its analogue Dgg16 (1,6-di-O-galloyl-beta-d-glucose). Human umbilical vein endothelial cells, ECV-304, were incubated with ox-LDL (50 mg/l), treated with corilagin or Dgg16 at different doses (0.0001-0.1 mmol/l), and then incubated with monocytes. Malondialdehyde (MDA) in the culture media was determined and the number of monocytes adhering to ECV-304 cells was counted with cytometry. In another experiment, the rat vascular smooth muscular cells (VSMC) were incubated in media with or without ox-LDL (50 mg/l), and with corilagin or Dgg16 also at different doses (0.0001-0.1 mol/l), the proliferation of which was assayed with MTT. The results showed that both corilagin and Dgg16 were able to decrease MDA, prevented ECV-304 cells from being adhering to by monocytes, and inhibited VSMC proliferation activated by ox-LDL. The results suggest that the two compounds are effective in inhibiting the progress of atherosclerosis by alleviating oxidation injury or by inhibiting ox-LDL-induced VSMC proliferation, which may be promising mechanisms for treating atherosclerosis. (+info)Chemopreventive action of emblica officinalis on skin carcinogenesis in mice. (6/31)
Chemoprevention with food phytochemicals is currently regarded as one of the most important strategies for cancer control. Emblica officinalis (Family: Euphorbiaceae) indigenous to India, is valued for its unique tannins and flavanoids, which contain very powerful antioxidant properties. The inhibition of tumor incidences by fruit extract of this plant has been evaluated on two-stage process of skin carcinogenesis in Swiss albino mice, induced by a single application of 7, 12-dimethyabenz(a)anthrecene (100 microg / 100 microl acetone), and two weeks later, promoted by repeated application of croton oil (1% in acetone/thrice a week) till the end of the experiment (16 weeks). The tumor incidence, tumor yield, tumor burdon and cumulative number of papillomas were found to be higher in the control (without EO treatment) as compared to experimental animals (EO treated). The differences in the values of the results of experimental groups were statistically analysed and found to be significant in comparison to the control group (p< 0.05). The present study demonstrates the chemopreventive potential of Emblica officinalis fruit extract on DMBA induced skin tumorigenesis in Swiss albino mice. (+info)Development and application of RAPD-SCAR marker for identification of Phyllanthus emblica LINN. (7/31)
Correct genotype identification of medicinal plant material remains important for botanical drug industry. Limitations of chemical and morphological approaches for authentication have generated need for newer methods in quality control of botanicals. The present study was carried out to develop DNA based marker for identification of Phyllanthus emblica LINN. A putative marker (1.1 kb) specific for P. emblica was identified by Random Amplified Polymorphic DNA (RAPD) technique. Sequence Characterized Amplified Region (SCAR) marker was developed from the RAPD amplicon. The SCAR marker was found useful for identification of P. emblica in its commercial samples and Triphalachurna, a multi-component Ayurvedic formulation. (+info)Emblica officinalis and its enriched tannoids delay streptozotocin-induced diabetic cataract in rats. (8/31)
PURPOSE: Aldose reductase (AR) has been a drug target because of its involvement in the development of secondary complications of diabetes including cataract. We have previously reported that the aqueous extract of Emblica officinalis and its constituent tannoids inhibit AR in vitro and prevent hyperglycemia-induced lens opacification in organ culture. The purpose of the current study was to investigate the effect of Emblica and its enriched tannoids on streptozotocin (STZ)-induced diabetic cataract in rats. METHODS: Diabetes was induced in Wistar-NIN rats by STZ (35 mg/kg body weight, intraperitoneally) and the animals were divided into three groups (Group II, III, and IV). The control rats (Group I) received only vehicle. While Group I and Group II animals received AIN-93 diet, rats in Groups III and IV received 0.2% of standardized mixture of Emblica tannoids and 2% of Emblica pericarp, respectively, in an AIN-93 diet for a period of eight weeks. Cataract progression due to hyperglycemia was monitored by slit-lamp biomicroscope and classified into four stages. At the end of the eight weeks, the animals were sacrificed and markers of the polyol pathway, oxidative stress, and alterations in protein content and crystallin profile in the lens were measured. Blood glucose and insulin levels were also determined. RESULTS: Both Emblica and its tannoids did not prevent STZ-induced hyperglycemia as assessed by blood glucose and insulin levels. However, slit lamp microscope observations indicated that these supplements delayed cataract progression. The present studies suggest that Emblica and its tannoids supplementation inhibited AR activity as well as sorbitol formation in the lens. The results also point out that Emblica and its tannoids might counter the polyol pathway-induced oxidative stress as there was a reversal of changes with respect to lipid peroxidation, protein carbonyl content, and activities of antioxidant enzymes. Emblica also prevented aggregation and insolubilization of lens proteins caused by hyperglycemia. CONCLUSIONS: The results provide evidence that Emblica and an enriched fraction of Emblica tannoids are effective in delaying development of diabetic cataract in rats. (+info)Phyllanthus emblica, also known as Indian gooseberry or Amla, is a plant species native to India and Southeast Asia, whose fruit is used in traditional medicine for its believed antioxidant, anti-inflammatory, and gastroprotective properties.
Phyllanthus emblica, also known as Emblica officinalis or Amla, is a plant species native to India and Southeast Asia. In the context of medicine, particularly in Ayurvedic medicine, the fruit of Phyllanthus emblica is used.
Medical definitions describe Phyllanthus emblica as a:
1. Rising drug: A substance of plant origin used in traditional Ayurvedic medicine, primarily in the Indian subcontinent.
2. Fruit of an Asian tree (Phyllanthus emblica) that contains various bioactive compounds such as phenolic acids, flavonoids, tannins, and alkaloids.
3. Traditional Ayurvedic remedy with antioxidant, anti-inflammatory, immunomodulatory, and gastroprotective properties.
4. A rich source of vitamin C and other nutrients such as calcium, iron, and carotene.
5. Used in various Ayurvedic formulations for treating conditions like diabetes, indigestion, jaundice, and skin disorders.
6. May help improve cognitive function, liver health, and cardiovascular health based on preliminary research. However, more extensive clinical trials are needed to confirm these potential benefits.
Phyllanthus is a genus of approximately 750-1000 species of flowering plants, including both herbs and shrubs, found primarily in tropical and subtropical regions, many of which have been used in traditional medicine for various purposes such as treating liver disorders, diarrhea, and diabetes, although scientific evidence supporting these uses is generally limited.
"Phyllanthus" is a genus of flowering plants and does not have a specific medical definition. However, certain species of Phyllanthus are used in traditional medicine and herbal remedies. For example:
* Phyllanthus amarus is used in Ayurvedic medicine for treating liver disorders and diabetes.
* Phyllanthus niruri is also used in traditional medicine for treating liver problems, kidney stones, and digestive issues.
* Phyllanthus emblica, also known as Indian gooseberry, is commonly used in Ayurvedic medicine for its antioxidant and anti-inflammatory properties.
It's important to note that while some Phyllanthus species have been studied for their potential medicinal benefits, more research is needed before they can be recommended as standard treatments. Additionally, herbal supplements can interact with prescription medications and may not be safe for everyone, so it's always best to consult with a healthcare provider before starting any new treatment regimen.
'Plant extracts' are defined as substances obtained from any plant material, including leaves, flowers, fruits, seeds, stems, roots, bark or wood, through various extraction methods, which may contain a range of bioactive compounds with potential therapeutic benefits, but also variability in composition and quality.
A plant extract is a preparation containing chemical constituents that have been extracted from a plant using a solvent. The resulting extract may contain a single compound or a mixture of several compounds, depending on the extraction process and the specific plant material used. These extracts are often used in various industries including pharmaceuticals, nutraceuticals, cosmetics, and food and beverage, due to their potential therapeutic or beneficial properties. The composition of plant extracts can vary widely, and it is important to ensure their quality, safety, and efficacy before use in any application.